Tremelimumab: Ph III MYSTIC amended

AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) amended the primary endpoints of the open-label, international Phase III MYSTIC trial of durvalumab (MEDI4736) with or

Read the full 235 word article

User Sign In